trial · primary record
Capecitabine
Gastric Neuroendocrine Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 67 |
| Primary completion | 2029-01-01 |
| Primary endpoint | Progression-free Survival (PFS) |
| Registry ID | NCT02595424 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:45.171Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02595424
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Capecitabine · approval
- Capecitabine · compound